| Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz, J Burkart, DM Geynisman, ... The Lancet Oncology 20 (4), 581-590, 2019 | 152 | 2019 |
| The future of immune checkpoint cancer therapy after PD-1 and CTLA-4 AW Hahn, DM Gill, SK Pal, N Agarwal Immunotherapy 9 (8), 681-692, 2017 | 107 | 2017 |
| Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA N Agarwal, SK Pal, AW Hahn, RH Nussenzveig, GR Pond, SV Gupta, ... Cancer 124 (10), 2115-2124, 2018 | 94 | 2018 |
| First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis AW Hahn, Z Klaassen, N Agarwal, B Haaland, J Esther, YY Xiang, ... European Urology Oncology 2 (6), 708-715, 2019 | 81 | 2019 |
| PD-1 checkpoint inhibition: Toxicities and management AW Hahn, DM Gill, N Agarwal, BL Maughan Urologic Oncology: Seminars and Original Investigations 35 (12), 701-707, 2017 | 71 | 2017 |
| Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer U Swami, PI Velho, R Nussenzveig, J Chipman, VS Santos, S Erickson, ... European Urology 78 (5), 652-656, 2020 | 63 | 2020 |
| Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma J Ma, J Kuzman, A Ray, BO Lawson, B Khong, S Xuan, AW Hahn, ... Scientific reports 8 (1), 4044, 2018 | 61 | 2018 |
| Overview of current and future first-line systemic therapy for metastatic clear cell renal cell carcinoma DM Gill, AW Hahn, P Hale, BL Maughan Current treatment options in oncology 19, 1-12, 2018 | 59 | 2018 |
| Independent validation of effect of HSD3B1 genotype on response to androgen-deprivation therapy in prostate cancer N Agarwal, AW Hahn, DM Gill, JM Farnham, AI Poole, L Cannon-Albright JAMA oncology 3 (6), 856-857, 2017 | 59 | 2017 |
| Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC … AW Hahn, DM Gill, B Maughan, A Agarwal, L Arjyal, S Gupta, J Streeter, ... Oncotarget 8 (20), 33614, 2017 | 55 | 2017 |
| Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment AW Hahn, CS Higano, ME Taplin, CJ Ryan, N Agarwal American Society of Clinical Oncology Educational Book 38, 363-371, 2018 | 51 | 2018 |
| Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer G Sonpavde, N Agarwal, GR Pond, RJ Nagy, RH Nussenzveig, AW Hahn, ... Cancer 125 (9), 1459-1469, 2019 | 46 | 2019 |
| Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial AW Hahn, J Chahoud, MT Campbell, DD Karp, J Wang, B Stephen, ... Investigational new drugs 39, 1405-1410, 2021 | 44 | 2021 |
| Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma AW Hahn, C Froerer, S VanAlstine, N Rathi, EB Bailey, DD Stenehjem, ... Clinical genitourinary cancer 16 (5), 365-368, 2018 | 40 | 2018 |
| The role of circulating tumor DNA in renal cell carcinoma PG Bergerot, AW Hahn, CD Bergerot, J Jones, SK Pal Current treatment options in oncology 19, 1-11, 2018 | 40 | 2018 |
| Acute megakaryocytic leukemia: what have we learned AW Hahn, B Li, P Prouet, S Giri, R Pathak, MG Martin Blood reviews 30 (1), 49-53, 2016 | 40 | 2016 |
| Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma JA Kuzman, DD Stenehjem, J Merriman, AM Agarwal, SB Patel, AW Hahn, ... BMC urology 17, 1-5, 2017 | 33 | 2017 |
| A population-based analysis of outcomes for small cell carcinoma of the breast by tumor stage and the use of radiation therapy F Hare, S Giri, JK Patel, A Hahn, MG Martin Springerplus 4, 1-7, 2015 | 28 | 2015 |
| Ibrutinib has some activity in Richter’s syndrome S Giri, A Hahn, G Yaghmour, MG Martin Blood cancer journal 5 (1), e277-e277, 2015 | 28 | 2015 |
| Germline Variant in HSD3B1 (1245 A> C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer AW Hahn, DM Gill, RH Nussenzveig, A Poole, J Farnham, ... Clinical genitourinary cancer 16 (4), 288-292, 2018 | 27 | 2018 |
Roberto NussenzveigScientistVerified email at hci.utah.edu
